For whoever doesn't know them yet, Adaptimmune is the company that genetically engineered T-cells to target NY-ESO in synovial sarcoma and melanoma. Their trial was initially at NIH and then extended to other locations:
Well, Adaptimmune released a lot of good news this week. They made a deal with GSK and now they were just granted breakthrough therapy designation by the FDA:
So far in their studies, only patients who were HLA-A2 positive could participate so many people were not eligible. It looks like they will try to develop the technology so it works for other HLA types which is great news.